Diagnosing Cystic Fibrosis in Adults

Abstract

Diagnosing cystic fibrosis (CF) in adulthood is not a rare occurrence for CF centers despite the popular belief that the diagnosis is achieved almost universally in childhood by means of newborn screening or early clinical presentation. The purpose of this review article is to highlight specific considerations of adult diagnosis of CF. Obtaining a diagnosis of CF at any age is exceptionally important to ensure optimal treatment, monitoring, and support. In the new era of more personalized treatment with the advent of transformative therapies targeting the underlying protein defect, accurate diagnosis is of increasing importance. This review highlights the diagnostic algorithm leading to a new diagnosis of CF in adults. The diagnosis is usually confirmed in the presence of a compatible clinical presentation, evidence of cystic fibrosis transmembrane conductance regulator (CFTR) protein dysfunction, and/or identification of variants in the CFTR gene believed to alter protein function. Achieving the diagnosis, however, is not always straightforward as CFTR protein function exists on a continuum with different organs displaying varying sensitivity to diminution in function. We highlight the current knowledge regarding the epidemiology of CF diagnosed in adults and outline the various clinical presentations, including pulmonary and extrapulmonary, which are more common in this population. We expand on the stepwise testing procedures that lead to diagnosis, paying particular attention to additional levels of testing which may be required to achieve an accurate diagnosis. There continues to be an important need for both pulmonary and other specialists to be aware of the potential for later presentation of CF, as the improvements in treatment over decades have had large positive impacts on prognosis for people with this condition.

Keywords

cystic fibrosis - diagnosis - late presentation - CFTR-related disorder - nasal potential difference - sweat test

Publication History

Article published online:
09 January 2023

• References

• 1 Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child 1938; 56 (02) 344-399
• 2 Di Sant'Agnese PE, Andersen DH. Cystic fibrosis of the pancreas. Prog Pediat Study 1948; (Suppl. 01) 160-176
• 3 Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23 (03) 545-549
• 4 Riordan JR, Rommens JM, Kerem B. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245 (4922): 1066-1073
• 5 Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med 2005; 11 (06) 513-518
• 6 Rodman DM, Polis JM, Heltshe SL. et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171 (06) 621-626
• 7 Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103 (04) 629-635
• 8 Barben J, Castellani C, Dankert-Roelse J. et al. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. J Cyst Fibros 2017; 16 (02) 207-213
• 9 Lim MTC, Wallis C, Price JF. et al. Diagnosis of cystic fibrosis in London and South East England before and after the introduction of newborn screening. Arch Dis Child 2014; 99 (03) 197-202
• 10 Middleton PG, Mall MA, Dřevínek P. et al; VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381 (19) 1809-1819
• 11 Heijerman HGM, McKone EF, Downey DG. et al; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394 (10212): 1940-1948
• 12 UK Cystic Fibrosis Registry 2021 Annual. Data Report Published online 2022. Accessed December 20, 2022 at: cysticfibrosis.org.uk/registry
• 13 Gan KH, Geus WP, Bakker W, Lamers CB, Heijerman HG. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax 1995; 50 (12) 1301-1304
• 14 Widerman E, Millner L, Sexauer W, Fiel S. Health status and sociodemographic characteristics of adults receiving a cystic fibrosis diagnosis after age 18 years. Chest 2000; 118 (02) 427-433
• 15 Farley H, Poole S, Chapman S, Flight W. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy. Postgrad Med J 2022; 98 (1159): 341-345
• 16 Padoan R, Quattrucci S, Amato A. et al; Data from the Italian Registry. The Diagnosis of cystic fibrosis in adult age. Diagnostics (Basel) 2021; 11 (02) 321
• 17 Castellani C, De Boeck K, De Wachter E, Sermet-Gaudelus I, Simmonds NJ, Southern KW. ECFS Diagnostic Network Working Group. ECFS standards of care on CFTR-related disorders: updated diagnostic criteria. J Cyst Fibros 2022;
• 18 Desai S, Wong H, Sykes J, Stephenson AL, Singer J, Quon BS. Analysis of the Canadian CF Registry. Clinical characteristics and predictors of reduced survival for adult-diagnosed cystic fibrosis. Ann Am Thorac Soc 2018; 15 (10) 1177-1185
• 19 Nick JA, Chacon CS, Brayshaw SJ. et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010; 182 (05) 614-626
• 20 Ramsey BW, Dorkin HL, Eisenberg JD. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328 (24) 1740-1746
• 21 Retsch-Bogart GZ, Quittner AL, Gibson RL. et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135 (05) 1223-1232
• 22 Flume PA, VanDevanter DR, Morgan EE. et al. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros 2016; 15 (04) 495-502
• 23 Rowe SM, Daines C, Ringshausen FC. et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 2017; 377 (21) 2024-2035
• 24 Barry PJ, Mall MA, Álvarez A. et al; VX18-445-104 Study Group. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med 2021; 385 (09) 815-825
• 25 Ramsey ML, Gokun Y, Sobotka LA. et al. Cystic fibrosis transmembrane conductance regulator modulator use is associated with reduced pancreatitis hospitalizations in patients with cystic fibrosis. Am J Gastroenterol 2021; 116 (12) 2446-2454
• 26 Gould MJ, Smith H, Rayment JH, Machida H, Gonska T, Galante GJ. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis. J Cyst Fibros 2022; 21 (04) 600-602
• 27 Freeman AJ. The impact of modulator therapies on pancreatic exocrine function: the good, the bad and the potentially ugly. J Cyst Fibros 2022; 21 (04) 560-561
• 28 Simmonds NJ. Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis. Paediatr Respir Rev 2019; 31: 6-8
• 29 Sosnay PR, Salinas DB, White TB. et al. Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses. J Pediatr 2017; 181S: S27 –S32, 32.e1
• 30 Farrell PM, White TB, Ren CL. et al. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. J Pediatr 2017; 181S: S4-S15 , 15.e1
• 31 Augarten A, Kerem BS, Yahav Y. et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C–>T mutation. Lancet 1993; 342 (8862): 25-26
• 32 Bombieri C, Claustres M, De Boeck K. et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011; 10 (2, suppl 2): S86-S102
• 33 Burgel PR, Fajac I, Hubert D. et al. Non-classic cystic fibrosis associated with D1152H CFTR mutation. Clin Genet 2010; 77 (04) 355-364
• 34 Morris-Rosendahl DJ, Edwards M, McDonnell MJ. et al. Whole-gene sequencing of CFTR reveals a high prevalence of the intronic variant c.3874-4522A>G in cystic fibrosis. Am J Respir Crit Care Med 2020; 201 (11) 1438-1441
• 35 Welcome to CFTR2 | CFTR2. Accessed October 15, 2022 at: https://cftr2.org/
• 36 Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol 2011; 741: 69-86
• 37 Solomon GM, Bronsveld I, Hayes K. et al. Standardized measurement of nasal membrane transepithelial potential difference (NPD). J Vis Exp 2018; 2018 (139) 57006
• 38 Yaakov Y, Kerem E, Yahav Y. et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 2007; 132 (04) 1219-1226
• 39 Wilschanski M, Famini H, Strauss-Liviatan N. et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17 (06) 1208-1215
• 40 Ooi CY, Dupuis A, Ellis L. et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?. Thorax 2014; 69 (03) 254-260
• 41 Tridello G, Menin L, Pintani E, Bergamini G, Assael BM, Melotti P. Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis. J Cyst Fibros 2016; 15 (05) 579-582
• 42 Aalbers BL, Yaakov Y, Derichs N. et al. Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism. J Cyst Fibros 2020; 19 (04) 627-631
• 43 Goubau C, Wilschanski M, Skalická V. et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 2009; 64 (08) 683-691
• 44 Derichs N, Sanz J, Von Kanel T. et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010; 65 (07) 594-599
• 45 Bagheri-Hanson A, Nedwed S, Rueckes-Nilges C, Naehrlich L. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. BMC Pulm Med 2014; 14 (01) 156
• 46 Wilschanski M, Yaakov Y, Omari I. et al. Comparison of nasal potential difference and intestinal current measurements as surrogate markers for CFTR Function. J Pediatr Gastroenterol Nutr 2016; 63 (05) e92-e97
• 47 Dekkers JF, Wiegerinck CL, de Jonge HR. et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19 (07) 939-945
• 48 Quinton P, Molyneux L, Ip W. et al. β-Adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012; 186 (08) 732-739
• 49 van Mourik P, Michel S, Vonk AM. et al. Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators. Transl Med Commun 2020; 5 (01) 1-8
• 50 Cuyx S, Ramalho AS, Corthout N. et al; Belgian Organoid Project. Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis. Thorax 2021; 76 (11) 1146-1149
• 51 Raynal C, Girodon E, Audrezet MP. et al. CFTR gene variants: a predisposition factor to aquagenic palmoplantar keratoderma. Br J Dermatol 2019; 181 (05) 1097-1099
• 52 Pasteur MC, Helliwell SM, Houghton SJ. et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162 (4, Pt 1): 1277-1284
• 53 Kerr C, Morrissy D, Horgan M, Plant BJ. Microbial clues lead to a diagnosis of cystic fibrosis in late adulthood. BMJ Case Rep 2020; 13 (04) e233470
• 54 Keating C, Poor AD, Liu X. et al. Reduced survival in adult cystic fibrosis despite attenuated lung function decline. J Cyst Fibros 2017; 16 (01) 78-84
• 55 Shteinberg M, Downey DG, Beattie D. et al. Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His . ERJ Open Res 2017; 3 (01) 00056-2016
• 56 Fajac I, Viel M, Gaitch N, Hubert D, Bienvenu T. Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease. Eur Respir J 2009; 34 (03) 772-773
• 57 Sly PD, Gangell CL, Chen L. et al; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368 (21) 1963-1970
• 58 Sermet-Gaudelus I, Girodon E, Vermeulen F. et al. ECFS standards of care on CFTR-related disorders: diagnostic criteria of CFTR dysfunction. J Cyst Fibros 2022;